Radiopharmaceutical firm Syncor International has received 510(k) clearance from the Food and Drug Administration for its palladium-103 seeds. The seeds are for use in treating localized prostate cancer. In December, the FDA cleared Woodland Hills,
Radiopharmaceutical firm Syncor International has received 510(k) clearance from the Food and Drug Administration for its palladium-103 seeds. The seeds are for use in treating localized prostate cancer. In December, the FDA cleared Woodland Hills, CA-based Syncors iodine-125 seeds, also for prostate cancer (SCAN 2/2/00). The company plans to market the two products under the trade name PharmaSeed.
In other Syncor news, the firm announced the resignation of Brad Nutter, executive vice president and COO. Nutter left Syncor on Feb. 11 for the position of president of Gambro Healthcare. While Syncor seeks a permanent replacement for Nutter, its pharmacy services executive team will report to president and CEO Robert Funari.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.